Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed at negative
regulatory components on T cells, such as cytotoxic T lymphocyte‐associated antigen 4 …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …

Immune checkpoint inhibitors (ICPis) have revolutionized the treatment of cancers by
engaging the patient's own immune system against the tumor (1-3). Checkpoint pathways …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …

Immune checkpoint inhibitors have dramatically improved cancer therapy for many patients.
These humanized monoclonal antibodies against various immune checkpoints (receptors …

Immune checkpoint inhibitors (CPIs) have significantly improved the outcome for patients
with cancer by effectively overcoming cancer resistance by allowing the host immune system …

Background Immune checkpoint inhibitors (ICPi) are a novel and promising anti-cancer
therapy. There are limited data on the incidence, risk factors and outcomes of acute kidney …

Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal
complications in use of these agents are not very common compared with other immune …

Immune checkpoint inhibitors (ICIs) are novel humanized monoclonal antibodies that
release the brakes on the immune system, resulting in the destruction of tumor cells. ICIs are …

Recent advances in immune checkpoint inhibitor (ICPI) development have led to major
improvements in oncology patient outcomes. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) …